Lixte Biotechnology LIXT Stock
Lixte Biotechnology Price Chart
Lixte Biotechnology LIXT Financial and Trading Overview
| Lixte Biotechnology stock price | 4.09 USD |
| Previous Close | 3.78 USD |
| Open | 3.75 USD |
| Bid | 0 USD x 0 |
| Ask | 0 USD x 0 |
| Day's Range | 3.7 - 4.35 USD |
| 52 Week Range | 0.64 - 4.45 USD |
| Volume | 258.69K USD |
| Avg. Volume | 2.09M USD |
| Market Cap | 12.29M USD |
| Beta (5Y Monthly) | 0.368 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.19 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
LIXT Valuation Measures
| Enterprise Value | 4.54M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Lixte Biotechnology Stock Price History
| Beta (5Y Monthly) | 0.368 |
| 52-Week Change | 75.75% |
| S&P500 52-Week Change | 13.16% |
| 52 Week High | 4.45 USD |
| 52 Week Low | 0.64 USD |
| 50-Day Moving Average | 1.69 USD |
| 200-Day Moving Average | 1.73 USD |
LIXT Share Statistics
| Avg. Volume (3 month) | 2.09M USD |
| Avg. Daily Volume (10-Days) | 1.05M USD |
| Shares Outstanding | 3.03M |
| Float | 2.53M |
| Short Ratio | 0.16 |
| % Held by Insiders | 18.43% |
| % Held by Institutions | 15.84% |
| Shares Short | 4.46K |
| Short % of Float | 0.16% |
| Short % of Shares Outstanding | 0.16% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2024 |
| Most Recent Quarter (mrq) | March 31, 2025 |
| Next Fiscal Year End | December 31, 2025 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -81.14% |
| Return on Equity (ttm) | -155.13% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -3324198 USD |
| Diluted EPS (ttm) | -1.45 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.38M USD |
| Total Cash Per Share (mrq) | 0.52 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 4.264 |
| Book Value Per Share (mrq) | -0.872 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -2943794 USD |
| Levered Free Cash Flow (ttm) | -1725609 USD |
Profile of Lixte Biotechnology
| Country | United States |
| State | CA |
| City | Pasadena |
| Address | 680 East Colorado Boulevard |
| ZIP | 91101 |
| Phone | 631 830 7092 |
| Website | https://lixte.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 2 |
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
Q&A For Lixte Biotechnology Stock
What is a current LIXT stock price?
Lixte Biotechnology LIXT stock price today per share is 4.09 USD.
How to purchase Lixte Biotechnology stock?
You can buy LIXT shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Lixte Biotechnology?
The stock symbol or ticker of Lixte Biotechnology is LIXT.
Which industry does the Lixte Biotechnology company belong to?
The Lixte Biotechnology industry is Biotechnology.
How many shares does Lixte Biotechnology have in circulation?
The max supply of Lixte Biotechnology shares is 5.7M.
What is Lixte Biotechnology Price to Earnings Ratio (PE Ratio)?
Lixte Biotechnology PE Ratio is now.
What was Lixte Biotechnology earnings per share over the trailing 12 months (TTM)?
Lixte Biotechnology EPS is -1.19 USD over the trailing 12 months.
Which sector does the Lixte Biotechnology company belong to?
The Lixte Biotechnology sector is Healthcare.
Lixte Biotechnology LIXT included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 23025.59 USD — |
+0.67
|
7.45B USD — | 22587.11 USD — | 23070.09 USD — | — - | 7.45B USD — |
| US Tech Health Care IXHC | 1204.14 USD — |
+1.48
|
— — | 1188.53 USD — | 1204.68 USD — | — - | — — |
- {{ link.label }} {{link}}